BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Combination therapy with HDACi and TKIs has demonstrated synergistic effects in CML: SAHA, combined with dasatinib, depleted BCR-ABL, and STAT5 in K562, LAMA-84, and BaF3 cells [14].